Back to results
US 2022/0054551 A1Published application
Compositions and methods for treating ceacam positive cancers
AssigneeA2 Biotherapeutics, Inc.
InventorsXueyin WANG, Carl Alexander KAMB, Han XU, Mark L. SANDBERG, Dora Toledo WARSHAVIAK
Life of this patent
Estimating the term…
Abstract
The disclosure provides immune cells comprising a first activator receptor specific to CEA, and a second inhibitory receptor, and methods of making and using same for the treatment of cancer.
Claims30
An immune cell comprising:
- a. a first receptor, comprising an extracellular ligand binding domain specific to CEA cell adhesion molecule 5 (CEA);
- and
- b. a second receptor, comprising an extracellular ligand binding domain specific to a non-target antigen lost in a CEA+ cancer cell,
- wherein the first receptor is an activator receptor responsive to CEA;
- and wherein the second receptor is an inhibitory receptor responsive to the non-target antigen.
2 more elements
A polynucleotide or polynucleotide system, comprising one or more polynucleotides comprising polynucleotide sequences encoding:
- a. a first receptor, comprising an extracellular ligand binding domain specific to CEA cell adhesion molecule 5 positive (CEA);
- and
- b. a second receptor, comprising an extracellular ligand binding domain specific to a non-target antigen that has been lost in a CEA+ cancer cell,
- wherein the first receptor is an activator receptor responsive to CEA on the CEA+ cancer cell;
- and wherein the second receptor is an inhibitory receptor responsive to the non-target antigen.
2 more elements
Dependencies are inferred from the claim text.